June 2007

Novel therapeutic approaches represent the latest advances in targeted cancer therapy that may one day provide clinicians with a better means of custom-tailoring cancer treatment. Eventually, treatments may be individualized based on unique sets of molecular targets.

The Academy delivers the latest news on biotech and oncology research, providing a link between the clinical world of cancer care and the university researchers who are pushing farther toward knowledge and discovery. In this issue: 1) University of Texas M.D. Anderson Cancer Center, Houston, TX: Assessment Model for Lung Cancer Risk 2) Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA: Diabetes Drug Boosts Efficacy of Platinum Chemotherapy Agents 3) University of Wisconsin-Madison Medical School, Madison, WI: Virtual Colonoscopy Safe and More Cost-effective than Optical Colonoscopy 4) Johns Hopkins University School of Medicine, Baltimore, MD: New Blood Test for Prostate Cancer Screening 5) Radcliffe Infirmary, Oxford, UK: Aspirin Use Can Prevent Colorectal Cancer 6) Ohio State University, Columbus, OH: Molecular Marker for Pancreatic Cancer

This issue features reports from: American Association for Cancer Research meeting April 14-18, 2007 Los Angeles, CA BIO International Convention May 6-9, 2007 Boston, MA

Topics covered in this issue include: 1) High Cancer Drug Costs Altering the Research and Treatment Dynamic 2) $128 Million Settlement to Physicians 3) Coinsurance Change for Medicare Beneficiaries for Colon Cancer Screening 4) Managed Care Penetration: Not a Source of Significant Variation in Rectal Surgery Follow-up 5) Specialty Pharmacy Distributors Likely to Be the Norm for Oncology Agents 6) Better Practices for Cancer-Related Infections 7) Radioimmunotherapy Underutilized in Lymphoma?

Physicians' Financial News focuses on news-making and/or notable companies in the oncology/biotech sector. In this issue: 1) Cell Therapeutics' Indolent NHL Agent Gets Fast Tracked 2) First Low-Molecular-Weight Heparin Approved for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer 3) ArQule Stands to Earn $123 Million in Deal with Kyowa 4) Dendreon's Prostate Cancer Immunotherapy Suffers Setback 5) Amgen Anemia Portfolio at Risk 6) Antisoma Could Gain $890 Million from Novartis Deal

The Clinical Trials reported in this issue are: PHASE I: CuraGen, TopoTarget Begin Study of HDAC Inhibitor Candidate as Combination Therapy for Soft Tissue Sarcomas Ambrilia's Therapeutic Peptide Shows Clinical Activity in Metastatic Prostate Cancer Patients PHASE II: Alchemia's Precursory Evaluation of mCRC Study Presents Positive Efficacy Data IsoRay's Cesium-131 Established as Front-Line Treatment for Early-Stage Prostate Cancer PHASE III: BDSI Closer to Filing NDA for Delivery Technology in Breakthrough Cancer Pain Market Tarceva Sees Continued Positive Clinical Data and Spurs Growth for OSI

Articles in this issue include: 1) Norway: Hopes for Trastuzamab Use in Endometrial Cancer 2) Switzerland: New Guidelines Highlight Use of Bisphosphonates in Elderly Patients With Bone Metastases 3) Italy: Bringing Out All of the Artillery to Fight Mesothelioma 4) Poland: Radiotherapy in Lung Cancer: Former Soviet Bloc Countries at a Disadvantage 5) United Kingdom: --Are More Transfusions Being Used in Patients With Cancer? --Watchful Waiting Advanced Even for Advanced Prostate Cancer --Exemestane Proven Useful for Breast Cancer After Switching From Tamoxifen

The articles featured in this issue are: 1) Supplemental Drug Application Submitted for Postoperative Nausea and Vomiting by John D. Zoidis, MD 2) Medicare Proposes Limits on Coverage for Erythropoiesis-Stimulating Drugs by John D. Zoidis, MD 3) Femara Reduces Risk of Early Breast Cancer Relapse in Postmenopausal Women by Prachi Patel-Predd 4) Researchers Develop Pancreatic Cancer Risk Model by Prachi Patel-Predd 5) Beyond BCG: New Bladder Cancer Treatments Offer Hope of Tailored, More Effective Therapies by Diane West 6) Doctor���¢�¯�¿�½�¯�¿�½s Own Brush With Bladder Cancer Gives Him Unique Insight to Patients���¢�¯�¿�½�¯�¿�½ Challenges by Diane West

Two separate studies show the relationship between hormone replacement therapy and women's cancers.

The first revision in 12 years, the new guidelines are based on a growing body of evidence-based research and emphasize communication with the patient regarding risk, treatment options, and potential outcomes.

With so many developments in the biotechnology industry, keeping up-to-date is more important than ever. Oncology & Biotech News is dedicated to helping practicing oncologists stay current on the latest therapeutic breakthroughs. To that end, we introduce two new departments�Global Reports and Reimbursement and Managed Care News�that provide an international view of oncology as well as a focus on practice management issues.